Valuation: Alcon

Market Cap 3.32TCr 2.91TCr 2.68TCr 2.49TCr 4.72TCr 3,16800Cr 4.79TCr 32TCr 12TCr 1,55500Cr 12TCr 12TCr 5,39200Cr P/E 2026 *
31.5x
P/E 2027 * 24.6x
Enterprise Value 3.58TCr 3.14TCr 2.89TCr 2.68TCr 5.09TCr 3,41600Cr 5.16TCr 35TCr 13TCr 1,67700Cr 13TCr 13TCr 5,81400Cr EV / Sales 2026 *
3.21x
EV / Sales 2027 * 2.94x
Free-Float
97.36%
Yield 2026 *
0.52%
Yield 2027 * 0.6%
Manager TitleAgeSince
Chief Executive Officer 60 01/07/2018
Director of Finance/CFO 58 08/04/2019
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 01/07/2018
Director/Board Member 63 01/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+30.08%0.00% - - 3.34TCr
+0.23%+5.57%-26.05%+2.06% 9.06TCr
-2.14%+1.71%-0.94%-22.71% 1.45TCr
+0.59%+5.99% - - 973.32Cr
-1.42%+15.21%-7.30%+590.84% 223.58Cr
-0.09%+1.93%-27.79%-64.27% 146.14Cr
+0.40%+12.99%+24.46%-2.09% 90Cr
-1.21%+5.26%-38.25%-28.39% 86Cr
-0.59%+1.99%+47.77%-29.84% 78Cr
-0.31%-11.82% - - 64Cr
Average -0.42%+3.59%-4.01%+63.66% 1.35TCr
Weighted average by Cap. +0.01%+5.07%-21.60%+9.30%

Financials

2026 *2027 *
Net sales 1.11TCr 975.64Cr 898.62Cr 834.12Cr 1.58TCr 1,06300Cr 1.61TCr 11TCr 4.19TCr 52TCr 4.18TCr 4.09TCr 1,80800Cr 1.18TCr 1.04TCr 953.43Cr 885Cr 1.68TCr 1,12700Cr 1.7TCr 11TCr 4.44TCr 55TCr 4.44TCr 4.34TCr 1,91900Cr
Net income 111.37Cr 98Cr 90Cr 83Cr 158.35Cr 11TCr 160.49Cr 1.08TCr 418.51Cr 5.21TCr 418.23Cr 409.05Cr 18TCr 137.97Cr 120.84Cr 111.3Cr 103.31Cr 196.18Cr 13TCr 198.83Cr 1.33TCr 518.49Cr 6.46TCr 518.14Cr 506.77Cr 22TCr
Net Debt 259.54Cr 227.3Cr 209.36Cr 194.33Cr 369.03Cr 25TCr 374.02Cr 2.51TCr 975.32Cr 12TCr 974.67Cr 953.29Cr 42TCr 154.04Cr 134.91Cr 124.26Cr 115.34Cr 219.03Cr 15TCr 221.99Cr 1.49TCr 578.87Cr 7.21TCr 578.49Cr 565.79Cr 25TCr
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA